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Evaluation of the Short- , Mid- , and Long- Term  
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Rheumatoid Arthritis
Ronald van Vollenhoven,1 Eun Bong Lee,2 Sander Strengholt,3 Christopher Mojcik,3 Hernan Valdez,3 
Sriram Krishnaswami,4 Pinaki Biswas,3 Irina Lazariciu,5 Anasuya Hazra,4 James D. Clark,6 Jennifer Hodge,3 
Lisy Wang,4 and Ernest Choy7
Objective. Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Altered lymphocyte cell 
counts and a potential association with increased infection rates have been reported in RA patients treated with JAK 
inhibitors. This analysis was undertaken to evaluate the short- , mid- , and long- term effects of tofacitinib on lympho-
cytes and infection rates in patients with RA.
Methods. In this post hoc analysis, absolute lymphocyte counts (ALCs) were obtained from phase III studies 
(12–24 months; n = 717–958) and phase I/II/III/long- term extension studies of tofacitinib (≤117 months) (All RA 
population; n = 7,061); lymphocyte subset counts (LSCs) were from phase II studies (1.5–6 months’ exposure; n = 
236–486), an ORAL Sequel vaccine substudy (~22 months; n = 198), and an ORAL Sequel lymphocyte substudy 
(~50 months; n = 55–1,035) of tofacitinib. The reversibil ity of ALC/LSC changes was evaluated. The relationship of 
ALC and LSC to infections was analyzed in the All RA population. The value of monitoring ALC alone was assessed 
by examining correlations between ALCs and LSCs.
Results. Tofacitinib treatment resulted in an initial increase in ALC versus pretreatment baseline, which gradually 
declined to steady state by ~48 months. CD4+ and CD8+ T cell counts decreased over long- term treatment, and ALC 
and LSC changes were reversible upon treatment cessation. Patients with ALCs of <500 cells/mm3 had an increased 
risk of serious infections. There was no strong association between CD4+ T cell, CD8+ T cell, B cell, or natural killer 
cell counts and serious infection incidence rates. ALC and CD4+ or CD8+ T cell counts correlated well (R = 0.65–0.86).
Conclusion. Our findings indicate that monitoring of ALC alone appears to be adequate to assess infection risk 
in tofacitinib- treated patients with RA.
INTRODUCTION
Tofacitinib is an oral JAK inhibitor for the treatment of 
rheumatoid arthritis (RA). The efficacy and safety of tofac-
itinib 5 mg and 10 mg twice daily, administered as mon-
otherapy or in  combination with conventional synthetic 
disease- modifying antirheumatic drugs (DMARDs) (mainly 
methotrexate [MTX]), in patients with moderately to severely 
active RA, have been demonstrated in phase II (1–5) and 
phase III (6–11) studies of up to 24 months’ duration and in 
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long- term extension (LTE) studies with up to 114 months of 
observation (12–14).
Tofacitinib partially and reversibly inhibits signaling of multi-
ple cytokines via the JAK/STAT pathway (15,16). Members of the 
common γ- chain family of cytokines, including interleukin- 2 (IL- 2), 
IL- 4, IL- 7, IL- 9, IL- 15, and IL- 21, signal through JAK1/JAK3 and 
are important for the development and proliferation of T cells, nat-
ural killer (NK) cells, and B cells (17–19); therefore, the modulation 
of cytokine signaling by tofacitinib might be expected to change 
immune cell counts and function over time, resulting in immune 
response suppression. Several studies within the tofacitinib devel-
opment program have evaluated cell- mediated immunity and 
humoral- mediated immunity (20–23).
Treatment with tofacitinib is associated with increased 
infections, likely related to immunomodulation, relative to find-
ings in patients treated with placebo. In a meta- analysis of inter-
ventional studies, rates of serious infections associated with 
tofacitinib in patients with moderately to severely active RA were 
similar to those reported with biologic DMARDs (24). A recent 
report noted a trend toward increasing risk of serious infection 
with lower lymphocyte counts (25). Confirmed decreases in 
absolute lymphocyte counts (ALCs) to <500 cells/mm3 occur 
during the first 3 months of exposure in ~0.04% of patients 
receiving tofacitinib at 5 mg or 10 mg twice daily; recommen-
dations state that these patients should discontinue treatment 
if this threshold is reached, due to an increased risk of serious 
infection (26,27).
Here, we evaluate the effects of tofacitinib on ALCs, lympho-
cyte subset counts (LSCs), and infection rates in patients with RA. 
The data are discussed in the context of immune function. Our 
primary objective was to characterize the short- , mid- , and long- 
term effects of tofacitinib treatment on ALCs and LSCs in patients 
with RA. Additional objectives were 1) to assess whether ALC and 
LSC changes observed with long- term tofacitinib treatment are 
reversible upon treatment cessation, 2) to evaluate the associa-
tion of infection rates in patients receiving tofacitinib with ALCs or 
LSCs, and 3) to assess the value of monitoring LSCs in addition 
to ALCs to mitigate the risk of infection.
PATIENTS AND METHODS
Patient populations. Patient data were derived from 
relevant phase I, II, and III and LTE studies from the tofacitinib 
development program. Patients were age ≥18 years and fulfilled 
the American College of Rheumatology 1987 revised criteria for 
classification of RA (28). Patients in LTE studies had previously 
participated in a qualifying phase I, II, or III index study of tofacitinib 
(12). An overview of the patient populations evaluated in this study 
is presented in Figure 1.
ALC assessments. ALCs were recorded as part of safety 
monitoring procedures throughout the tofacitinib RA clinical  program.
Short- term changes. Short- term changes in ALCs were as-
sessed in 2 phase III studies: ORAL Standard (NCT00853385) 
and ORAL Start (NCT01039688). ORAL Standard was a study 
to evaluate tofacitinib plus MTX versus adalimumab plus MTX 
over 12 months in 717 patients with RA and prior inadequate re-
sponse to MTX (MTX- IR) (11). ORAL Start (NCT01039688) eval-
uated tofacitinib versus MTX over 24 months in 958 MTX- naive 
patients with RA (9).
Long- term changes. Long- term changes in ALCs were 
evaluated using pooled data from studies of tofacitinib, across 
the entire duration of tofacitinib exposure (phases I, II, and III and 
LTE “All RA” population [n = 7,061], up to 117 months of treat-
ment [median ~36 months] overall; ORAL Sequel lymphocyte 
substudy database lock March 02, 2017). A detailed study list is 
provided in Figure 1.
LSC assessments. Short- term changes. Short- term 
changes in LSCs were assessed using data from 3 phase II stud-
ies (NCT00147498, NCT00413660, and NCT00550446) of 1.5–6 
months’ duration (n = 236–486 contributing to each LSC subtype 
at baseline). LSCs were not collected within any of the phase III 
or IIIb/IV studies.
Mid- term changes. Mid- term changes in LSCs were as-
sessed using data from a vaccine substudy of ORAL Sequel 
(NCT00413699) in patients who had received tofacitinib 10 mg 
twice daily for a median of 22 months (up to 1,632 days) before 
enrollment into the vaccine substudy (n = 198).
Long- term changes. Long- term changes in LSCs were as-
sessed using data from a lymphocyte substudy of ORAL Sequel 
(NCT00413699) in patients who had previously received tofaci ti-
nib 5 mg or 10 mg twice daily for a median of ~50 months before 
enrollment into the lymphocyte substudy. The lymphocyte sub-
study comprised 3 cohorts (Figure 1). Cohort 1 was investigated 
to ascertain the effects of long- term treatment with tofacitinib 
for a further 2 years in 1,035 patients (~50 months prior tofac-
itinib exposure). Cohort 2 evaluated whether the effects of to-
facitinib on LSC were reversible upon temporary withdrawal (for 
4 weeks) after long- term treatment in 55 patients (~50 months’ 
prior exposure). In cohort 3, the long- term effects of tofacitinib 
in patients enrolling only from the qualifying zoster vaccine study 
(A3921237) were evaluated (~4 months’ prior exposure; n = 71) 
(NCT02147587).
Analyses. ALCs and LSCs were ascertained and described 
by dose and visit over time, via descriptive statistics, line graphs, and 
box plots. For evaluations of LSC stability during long- term treat-
ment, reference ranges were derived from pretreatment baseline 
values (5th–95th percentile) in the tofacitinib development program 
in RA, and verified against values reported in literature (see Supple-
mentary Table 1, on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40780/abstract). Lympho-
cyte subsets were evaluated by flow cytometric analysis at a central 
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laboratory, and included the following: total T cells (CD3+), CD4+ 
T helper cells (CD3+CD4+), CD8+ cytotoxic T cells (CD3+CD8+), 
NK cells (CD3−CD16+CD56+), and B cells (CD3−CD19+).
The reversibility of long- term changes in ALC was inves-
tigated during follow- up of patients in the All RA population 
who permanently discontinued tofacitinib treatment due to 
confirmed ALC of <500 cells/mm3. The reversibility of short- 
term changes in LSC was evaluated using data from phase II 
study NCT00147498, in which patients received tofacitinib for 
6 weeks, followed by treatment withdrawal for 6 weeks. The 
reversibility of long- term changes in LSCs was evaluated in 
cohort 2 of the lymphocyte substudy through a 4- week tempo-
Figure 1. Overview of the study and analysis populations. * = Prior tofacitinib exposure. † = ORAL Strategy is a phase IIIb/IV study. ‡ = Power 
calculations indicated that these sample sizes (patients with available pretreatment baseline data) were adequate to detect long- term changes 
of ≥20% in each of the lymphocyte subset counts (LSCs) with at least 80% probability. § = Nearly all patients were originally participants in 
phase III studies and thus did not have pretreatment baseline LSC data. P = phase; LTE = long- term extension; ALC = absolute lymphocyte 
count; RA = rheumatoid arthritis; BID = twice daily; Q2W = every 2 weeks; MTX = methotrexate; NK = natural killer; LSS = lymphocyte substudy.
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rary withdrawal phase in patients previously treated with tofaci-
tinib for a median of ~50 months. Patients in cohort 2 had a 
≥40% reduction in ALC from the index study baseline and an 
ALC of ≤1,000 cells/mm3 at the last visit prior to entry into the 
lymphocyte substudy.
The clinical effect of changes in ALC and LSC on risk of 
infections was analyzed using the All RA population. To ascer-
tain whether modifications to current monitoring and discontin-
uation recommendations (ALC <500 cells/mm3) are warranted, 
incidence rates of infections were calculated by ALC categories 
and by patient groups, defined by quartiles of nadir LSC values 
for each patient.
To evaluate the value of monitoring LSCs in addition to 
ALC to minimize risk of infection, the relationship between 
LSCs and ALC was assessed by examining their correla-
tion before and after tofacitinib treatment. The maintenance 
of a correlation between ALC and LSC at low cell counts 
was also evaluated. Scatterplots for each pair of observations 
(ALC, LSC) and estimated Pearson correlation coefficients 
were generated at pretreatment baseline and after tofacitinib 
exposure.
A Cox regression model was used to identify and assess fac-
tors associated with time to confirmed lymphopenia (ALC <500 
cells/mm3). Each factor was assessed individually, and a multi-
variable model was developed using an automated, backward 
elimination procedure.
RESULTS
Changes in ALC over time. Short- term changes in ALC: 
data from ORAL Standard and ORAL Start. In the ORAL Standard 
study (MTX- IR), increases in ALC were observed at month 1 in 
both tofacitinib plus MTX treatment groups and the adalimumab 
plus MTX treatment group, but these did not persist in the tofaci-
Figure 2. Median change from baseline in absolute lymphocyte counts (ALCs) in rheumatoid arthritis (RA) patients from the phase III ORAL 
Standard study (0–12 months) (A), the phase III ORAL Start study (0–24 months) (B), and the phase I/phase II/phase III/long- term extension All 
RA population (0–114 months) (C). Data reported here for the All RA population include patients experiencing up to 114 months of exposure to 
tofacitinib; however, due to limited numbers of patients with data after month 102, interpretations should be made with caution. Only 1 patient 
had data at month 117, and that data point was therefore removed. Q1, Q3 = first through third quartiles; BID = twice daily; MTX = methotrexate.
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tinib plus MTX groups (Figure 2A). At month 12, median decreases 
in ALC from baseline were −190 cells/mm3 with tofacitinib 5 mg 
twice daily plus MTX and −310 cells/mm3 with  tofacitinib 10 mg 
twice daily plus MTX. In ORAL Start (MTX- naive), increases in ALC 
from baseline were observed from month 1 to month 3, followed 
by decreases to month 24; at month 12, the median change in 
ALC was −110 cells/mm3 with tofacitinib 5 mg twice daily and 
–150 cells/mm3 with tofacitinib 10 mg twice daily; at month 24, 
decreases were numerically greater with tofacitinib 5 mg twice 
daily (–330 cells/mm3) and tofacitinib 10 mg twice daily (–430 
cells/mm3) as monotherapy compared to MTX monotherapy 
(−170 cells/mm3) (Figure 2B).
Long- term changes in ALC: data from the All RA popu-
lation. In the All RA population, the median ALC in tofacitinib- 
treated patients declined by ~24% from pretreatment baseline 
to 48 months, stabilizing at approximately –400 cells/mm3 (Fig-
ure 2C). Despite stable median ALC values after 48 months, 80 
patients (1.2%; 25 of 2,983 patients in the tofacitinib 5 mg twice 
daily group and 55 of 3,914 patients in the tofacitinib 10 mg 
twice daily group) experienced a confirmed (2 sequential mea-
surements) ALC of <500 cells/mm3. Fifty- eight of these 80 pa-
tients were from the LTE studies. At the time of the event, 64 of 
the 80 patients were receiving combination therapy (tofacitinib 
plus background treatment) and 16 patients were receiving to-
facitinib monotherapy.
Changes in LSCs over time. Short-term, mid-term, and 
long-term changes in LSCs are shown in Figure 3. In the phase II 
studies of tofacitinib in RA, treatment with tofacitinib 5 mg twice 
daily for up to 6 months (short-term) was associated with a min-
imal decrease from baseline in CD3+, CD4+, and CD8+ T  cell 
counts; B cell counts increased from baseline, while NK cell 
counts decreased. At study entry in the ORAL Sequel vaccine 
substudy, treatment with tofacitinib for a median of 22 months 
(mid-term) was associated with a decrease from baseline in CD3+, 
CD4+, and CD8+ T cell counts and a slight decrease in B cell and 
NK cell counts. Treatment with tofacitinib for ~50 months from 
index study baseline to entry into the ORAL Sequel lymphocyte 
substudy (long-term) was associated with a decrease in CD3+, 
CD4+, and CD8+ T cell counts, a minimal change in B cell counts, 
and a large increase in NK cell counts in the subset of patients 
with available pretreatment baseline data. Short- , mid- , and long- 
term changes in CD4+ T cell counts and in CD8+ T cell counts 
were observed to be similar.
Stability of LSCs during extended long- term treat-
ment. Patients in cohort 1 entered the lymphocyte substudy after 
a median of ~50 months of treatment in ORAL Sequel. During the 
next 27 months, there was no change in CD3+ T cell counts (Sup-
plementary Figure 1A, on the Arthritis & Rheumatology web site 
at http://onlinelibrary.wiley.com/doi/10.1002/art.40780/abstract), 
CD4+ or CD8+ T cell counts (data not shown; results similar to 
CD3+ T cell results), NK cell counts (Supplementary Figure 1B), 
or B cell counts (Supplementary Figure 1C), and the long- term 
effects of tofacitinib in this study were reflective of steady state.
The proportion of patients with LSC values below RA refer-
ence ranges for T cells and NK cells, and above the RA refer-
ence range for B cells in the lymphocyte substudy (cohort 1) is 
shown in Supplementary Table 2 (http://onlinelibrary.wiley.com/
doi/10.1002/art.40780/abstract). Across all visits, despite stable 
Figure 3. Median percentage change from baseline in lymphocyte subset counts (LSCs) in rheumatoid arthritis patients from phase II studies 
of tofacitinib 5 mg twice daily (short- term), from the ORAL Sequel vaccine substudy of tofacitinib 10 mg twice daily (mid- term), and at entry 
into the ORAL Sequel lymphocyte substudy (tofacitinib 5 mg or 10 mg twice daily) (long- term). * = Includes only the subgroup of patients with 
pretreatment baseline LSC data (for CD3+ T cells, B cells, and natural killer [NK] cells, n = 14; for CD4+ and CD8+ T cells, n = 10). † = Cohort 
1 type 1, i.e., the subgroup of patients in cohort 1 who originally participated in the phase II program and had pretreatment baseline data (for 
CD3+ T cells and B cells, n = 124; for CD4+ and CD8+ T cells, n = 51; for NK cells, n = 121). LV = last visit; M = month; NM = not measured.
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mean changes over time, CD3+, CD4+, and CD8+ T cell counts 
were below the RA reference range in ~13–18%, 17–21%, and 
12–19% of the patients, respectively, after long- term tofacitinib 
treatment. B cell counts above the RA reference range were 
recorded in ~2–6% of the patients, and NK cell counts were 
below the RA reference range in ≤0.9% of the patients. These 
proportions were consistent across visits.
Reversibility of changes in ALC and LSC values over 
time. Reversibility of changes in ALCs after long- term treat-
ment. Of 80 patients in the All RA population with a confirmed 
ALC of <500 cells/mm3 during treatment with tofacitinib, 88% 
(n = 70) had ALCs in the lymphopenic range (<1,500 cells/mm3) 
prior to tofacitinib initiation (Table 1). In 70 of 75 patients (93%) 
with follow- up ALC data after the confirmed ALC of <500 cells/
mm3 during tofacitinib treatment, the ALC increased to ≥500 
cells/mm3 (median 3–6 weeks following tofacitinib discontinu-
ation) (Table  1). In the remaining 5 patients, the ALC of <500 
cells/mm3 persisted for the entire duration of their follow- up 
(0.5–6 months). One patient had a diagnosis of lymphoma, and 
another had a diagnosis of acute promyelocytic leukemia, when 
low ALCs occurred. The remaining 3 patients discontinued from 
the study due to lymphopenia, per protocol requirement. Of the 
5 patients who had no follow- up ALC data after the confirmed 
ALC of <500 cells/mm3, 4 either discontinued or were hospi-
talized for a serious adverse event, and 1 completed the study 
with no occurrence of an adverse event associated with the lym-
phopenia event.
Reversibility of changes in LSCs after short- term treatment. 
The reversibility of LSCs (toward baseline values) was evaluat-
ed in a 6- week withdrawal phase following a 6- week treatment 
phase in the phase II study A3921019/NCT00147498. Observed 
changes in T cell counts in patients treated with tofacitinib 5 
mg twice daily were small and similar to changes with placebo 
treatment. This resulted in similar distributions of T cell counts 
during tofacitinib treatment and following treatment withdrawal, 
compared to placebo (data not shown). At week 6 of treatment, 
a 29% median increase from baseline in B cell counts was ob-
served with tofacitinib 5 mg twice daily; after the treatment with-
drawal phase, B cell counts decreased toward baseline levels 
and were similar to those in the placebo group. A 22% median 
decrease in NK cells was observed at week 6 of treatment with 
tofacitinib 5 mg twice daily; after the treatment withdrawal phase, 
NK cell counts increased toward baseline levels and were similar 
to those in patients who received placebo. For both NK cells 
and B cells, the median percentage change from pretreatment 
baseline at week 12 was close to 0 with tofacitinib 5 mg twice 
daily, indicating complete reversibility of the observed changes.
Reversibility of changes in LSCs after long- term treatment. 
The lymphocyte substudy (cohort 2) assessed reversibility of 
changes in LSCs after temporary withdrawal of tofacitinib treat-
ment for 4 weeks, following treatment for ~50 months. In 12 of 
22 patients (54.5%), 11 of 26 patients (42.3%), and 12 of 17 pa-
tients (70.6%) who had low CD3+, CD4+, or CD8+ T cell counts, 
respectively, values returned to within the RA reference range 
after the 4- week withdrawal (for LSC cutoff values, see Sup-
plementary Table 1, http://onlinelibrary.wiley.com/doi/10.1002/
art.40780/abstract).
After the 4- week withdrawal, B cell and NK cell counts 
remained within the RA reference range in the majority of patients; 
no patient had an NK cell value below the reference range or a B 
cell value above the reference range. Of 2 patients who had high 
NK cell values, the level returned to within the RA reference range 
in 1 but remained above the reference range in the other. Three 
patients had low B cell values prior to tofacitinib withdrawal; the 
level had returned to within the RA reference range at week 4 in 1 
but remained below the reference range in the other 2.
Association of ALC and LSC with infection rates 
following long- term treatment. Incidence rates of seri-
ous infections and herpes zoster in the All RA safety population 
(n = 7,061) are presented in Table  2. The incidence rates of 
serious infections following a confirmed ALC of <500 cells/mm3 
were higher versus ALC categories ≥500 cells/mm3, and herpes 
Table 1. Baseline ALC categories patients in the All RA population 
who developed an ALC of <500 cells/mm3 during tofacitinib 
treatment, and time to first ALC of ≥500 cells/mm3 in patients in 
the All RA population who had a confirmed ALC of <500 cells/mm3 
during tofacitinib treatment and discontinued treatment at any time 
during the study*
No. (%) of patients/median 
time to first observation
Baseline ALC, cells/mm3
<500 4 (5.0)
≥500 to <750 22 (27.5)
≥750 to <1,000 19 (23.8)
≥1,000 to <1,500 25 (31.3)
≥1,500 8 (10.0)
Missing data 2 (2.5)
Total 80 (100)
First ALC of ≥500 cells/mm3 
after tofacitinib discontin-
uation, cells/mm3
≥500 to <1,000 61 (87.1)/6.0 weeks
≥1,000 to <1,500 8 (11.4)/4.4 weeks
≥1,500 1 (1.4)/2.9 weeks
Total 70 (100)†
* Baseline data on absolute lymphocyte counts (ALCs) were ob-
tained from the index study. All RA = rheumatoid arthritis patients 
from the tofacitinib phases I, II, and III and long- term extension 
studies. 
† Five patients whose ALC never reached ≥500 cells/mm3 after con-
firmed ALC <500 cells/mm3 during tofacitinib treatment, as well as 
5 patients without available follow- up ALC data, were not included. 
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zoster generally showed an increasing risk with lower ALC val-
ues. The rate of opportunistic infections also exhibited a trend 
toward an increase with decreasing ALC (data not shown), but 
there were too few cases to draw meaningful conclusions.
Table  3 shows the relationship between LSCs and the 
risk of serious infections and herpes zoster. Overall, there were 
generally no strong associations between LSCs (CD3+ T cells, 
CD4+ T cells, CD8+ T cells, NK cells, and B cells) and serious 
infections or herpes zoster.
A Cox regression analysis was performed to identify and 
assess potential risk factors for lymphopenia (i.e., ALC <500 cells/
mm3). The results showed that patients with lower ALCs at base-
line (P < 0.0001), older age (P = 0.0012), higher tofacitinib dose 
(P = 0.0071), and those receiving background MTX (P = 0.0068) 
were at increased risk.
Correlation between ALCs and LSCs: utility of LSC 
monitoring. LSCs did not appear to be strongly associated 
with infection events; hence, if subset counts correlate well with 
ALCs, additional measurement of LSCs would not add value 
over and above the ALC to minimize risk of infection. The rela-
tionship between CD3+ T cell counts and ALCs was evaluated 
by estimating Pearson correlation coefficients (R) at pretreatment 
baseline (phase II baseline) and after short- term (phase II post-
baseline), mid- term (ORAL Sequel vaccine substudy entry), and 
long- term (ORAL Sequel lymphocyte substudy entry) treatment 
with tofacitinib. A high degree of correlation was seen at baseline 
(R = 0.79), which increased with long- term tofacitinib treatment 
(R = 0.89), indicating that changes in ALCs reflect changes in 
CD3+ T cell counts. This correlation was also observed at low 
values, i.e., low ALCs were associated with low CD3+ T cell 
counts (data not shown). Comparable results were observed for 
CD4+ T cell counts and ALCs (R = 0.82–0.86; Supplementary 
Figure 2A, http://onlinelibrary.wiley.com/doi/10.1002/art.40780/
abstract), likely because CD4+ T cells constituted ~50% of the 
ALC at baseline. The correlation between CD8+ T cell counts 
and ALCs was only slightly lower at baseline and after tofacitinib 
treatment (R = 0.65–0.70) versus that observed with CD4+ T 
cells (Supplementary Figure 2B).
In contrast to CD4+ and CD8+ T cell counts, a poor corre-
lation between ALC and NK cell counts was noted at baseline 
(R = 0.27), which improved with long- term tofacitinib treatment 
(R = 0.47). B cell counts and ALCs were moderately correlated at 
baseline (R = 0.61), with the correlation slightly decreasing follow-
ing long- term tofacitinib treatment (R = 0.55).
DISCUSSION
This post hoc pooled analysis of tofacitinib therapy in patients 
with RA evaluated the short- , mid- , and long- term effects of tofac-
itinib on ALCs and LSCs, the reversibility of changes in ALCs or 
LSCs, the association between ALCs/LSCs and infections, and 
the value of monitoring LSCs in addition to ALCs. A summary 
of the effects of tofacitinib on immune cells is presented in Sup-
plementary Table 3, on the Arthritis & Rheumatology web site at 
http://onlinelibrary.wiley.com/doi/10.1002/art.40780/abstract.
Tofacitinib treatment initially resulted in a transient increase in 
ALC, followed by a gradual decline to steady state by ~48 months. 
Table 2. Incidence rates of serious infections and herpes zoster by confirmed ALC category in the All RA population*
Confirmed ALC, 
cells/mm3
Serious infection Herpes zoster
n
No. (%) of 
patients with 
event
IR (95% CI) following 
confirmed ALC† n
No. (%) of 
patients with 
event
IR (95% CI) following 
confirmed ALC†
Missing data 35 0 (0) 35 1 (2.9)
≥2,000 6,092 94 (1.5) 2.4 (1.9–2.9) 6,092 113 (1.9) 2.9 (2.4–3.5)
≥1,500 to <2,000 4,477 130 (2.9) 2.3 (2.0–2.8) 4,427 177 (4.0) 3.3 (2.9–3.9)
≥1,000 to <1,500 4,271 215 (5.0) 2.4 (2.1–2.7) 4,154 311 (7.5) 3.7 (3.3–4.2)
≥750 to <1,000 1,706 83 (4.9) 2.6 (2.0–3.2) 1,589 122 (7.7) 4.3 (3.6–5.1)
≥500 to <750 614 48 (7.8) 4.0 (2.9–5.3) 568 55 (9.7) 5.3 (4.0–6.9)
<500 76 6 (7.9) 7.1 (2.6–15.5) 67 3 (4.5) 4.2 (0.9–12.2)
Overall 7,061 576 (8.2) 2.5 (2.3–2.7) 7,061 782 (11.1) 3.6 (3.4–3.9)
* Only patients with at least 2 visits at which absolute lymphocyte counts (ALCs) were obtained after the tofacitinib start date were included 
in the analysis. ALC was monitored independently of infection events. Patients with an ALC of <500 cells/mm3 discontinued tofacitinib treat-
ment and continued to be followed up to resolution or until the ALC was determined by the investigator to be stabilized. All RA = rheumatoid 
arthritis patients from the tofacitinib phases I, II, and III and long- term extension (LTE) studies; 95% CI = 95% confidence interval. 
† Incidence rates (IRs) are the number of patients with events per 100 patient- years and are based on events occurring after the confirmed 
ALC value was reached, i.e., an event is counted in a category if the event occurred only after the patient reached that category and did not 
occur while the patient was in any of the previous categories. For patient- years, the total follow- up time was calculated up to the day of the 
first event, subject to a risk period of 28 days beyond the last dose or to the data cutoff date. Gaps in dosing between index and LTE studies 
are included up to 28 days or to the data cutoff date. 
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In contrast, adalimumab- treated patients in the ORAL Standard 
trial experienced a sustained increase in ALC over 12 months, and 
MTX- treated patients in ORAL Start showed smaller decreases 
compared to tofacitinib- treated patients over 24 months. The 
different populations evaluated in these studies (MTX- naive ver-
sus MTX- IR) should, however, be acknowledged. Approximately 
1% of patients in the All RA population experienced a confirmed 
ALC of <500 cells/mm3, and 80% of these patients were receiv-
ing tofacitinib plus background therapy at the time of the event. 
In most patients who permanently discontinued tofacitinib treat-
ment due to an ALC of <500 cells/mm3, the ALC reverted to ≥500 
cells/mm3 between 3 and 6 weeks after discontinuation. Patients 
receiving tofacitinib with a confirmed nadir ALC of <500 cells/mm3 
had an increased risk of serious infection, while herpes zoster 
showed a trend toward an increasing risk with lower ALC values. 
The rate of opportunistic infections also showed a trend toward 
increases with decreasing ALC, but there were too few cases to 
draw meaningful conclusions. Given that lymphopenia is associ-
ated with an increased risk of serious infections during tofacitinib 
treatment (29), ALC evaluation at baseline and monitoring every 3 
months is recommended.
Initiation of tofacitinib is not recommended in patients with 
an ALC of <500 cells/mm3, and therapy should be discontinued 
in those developing a confirmed ALC of <500 cells/mm3 dur-
ing treatment (26). Patients receiving tofacitinib with a confirmed 
nadir ALC of between 500 and <750 cells/mm3 showed a trend 
toward increased risk of serious infection and herpes zoster, 
which is relevant to the recommendation in the European Union 
label to interrupt dosing within this range until ALC returns to 
>750 cells/mm3, due to increased risk of infection (27). A higher 
Table 3. Incidence rates (95% CI) of serious infections and herpes zoster by quartile of nadir CD3+ T cell, 
CD4+ T cell, CD8+ T cell, and NK cell counts, and zenith B cell counts, in the All RA population*
LSC, quartile,  
×1,000 cells/mm3
Serious infection Herpes zoster
n/no. with 
event IR (95% CI)
n/no. with 
event IR (95% CI)
CD3+ T cells
Q1, <0.62 531/25 0.85 (0.55–1.26) 533/109 4.17 (3.42–5.03)
Q2, 0.62 to <0.90 533/28 1.07 (0.71–1.55) 534/82 3.42 (2.72–4.25)
Q3, 0.90 to <1.26 533/30 1.37 (0.92–1.96) 539/73 3.54 (2.78–4.45)
Q4, ≥1.26 534/40 2.04 (1.46–2.78) 536/61 3.31 (2.53–4.25)
CD3+CD4+ T cells
Q1, <0.39 353/11 0.53 (0.26–0.95) 355/76 4.12 (3.25–5.16)
Q2, 0.39 to <0.55 354/11 0.58 (0.29–1.04) 356/53 3.05 (2.28–3.99)
Q3, 0.55 to <0.76 353/12 0.71 (0.37–1.24) 357/45 2.83 (2.07–3.79)
Q4, ≥0.76 354/15 1.15 (0.64–1.90) 357/28 2.26 (1.50–3.27)
CD3+CD8+ T cells
Q1, <0.13 351/12 0.60 (0.31–1.04) 353/75 4.25 (3.35–5.33)
Q2, 0.13 to <0.21 356/9 0.50 (0.23–0.94) 359/49 2.90 (2.14–3.83)
Q3, 0.21 to <0.31 353/13 0.75 (0.40–1.28) 356/43 2.64 (1.91–3.56)
Q4, ≥0.31 354/15 1.07 (0.60–1.77) 357/35 2.64 (1.84–3.68)
B cells (CD3−CD19+)
Q1, <0.14 532/46 2.01 (1.47–2.68) 535/101 4.87 (3.97–5.92)
Q2, 0.14 to <0.22 534/27 1.09 (0.72–1.58) 536/83 3.65 (2.90–4.52)
Q3, 0.22 to <0.33 539/26 1.05 (0.69–1.54) 541/74 3.23 (2.54–4.05)
Q4, ≥0.33 536/24 0.97 (0.62–1.45) 540/67 2.92 (2.26–3.71)
NK cells (CD3−CD16+CD56+)
Q1, <0.07 427/34 1.70 (1.18–2.37) 429/58 3.16 (2.40–4.08)
Q2, 0.07 to <0.12 426/14 0.69 (0.38–1.17) 429/61 3.27 (2.50–4.20)
Q3, 0.12 to <0.18 429/18 0.85 (0.50–1.34) 432/62 3.19 (2.44–4.08)
Q4, ≥0.18 428/15 0.71 (0.40–1.17) 431/55 2.78 (2.10–3.62)
* Incidence rates (IRs) are the number of patients with events per 100 patient- years. Events are counted 
up to 28 days beyond the last dose or to the data cutoff date. 95% CI = 95% confidence interval; NK = 
natural killer; All RA = rheumatoid arthritis patients from the tofacitinib phases I, II, and III and long-term 
extension studies; LSC = lymphocyte subset count; Q = quartile. 
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threshold has the potential to avoid more infections, but may 
also disproportionately exclude patients who could benefit from 
tofacitinib and not experience a serious infection (30).
Regarding LSCs, tofacitinib treatment resulted in 1) a slight 
initial decrease in T cell counts compared to pretreatment baseline, 
which decreased further with mid- to long- term treatment, 2) an 
initial decrease in NK cell counts, followed by a shift to increased 
NK cell counts with mid- to long- term treatment, and 3) an initial 
increase in B cell counts, which returned to baseline with long- term 
treatment. Reversible decreases in NK cells and increases in B 
cells with tofacitinib have been reported previously (20). For all cell 
types evaluated, no further progressive decline in LSCs occurred 
in the lymphocyte substudy. Withdrawal of tofaci tinib for 4 weeks 
in patients previously treated with tofacitinib for ~50 months 
demonstrated that changes in T cell and B cell levels are reversi-
ble, although the increase in NK cells upon treatment withdrawal is 
somewhat counterintuitive given the observed increases in NK cell 
counts over long- term tofacitinib treatment. Potential mechanisms 
for this phenomenon are discussed below. Also, there were no 
strong associations between LSCs and serious infections. ALCs 
correlated well with CD4+ T cell/CD8+ T cell counts; hence, spe-
cific CD4+ T cell or CD8+ T cell monitoring would be unlikely to 
further minimize infection risk. CD4+ and CD8+ T cells together 
constitute ~70% of ALCs (31,32), and changes in these subtypes 
therefore should be reflected in ALCs.
Similar early effects on NK, B, and T cells have been reported 
with other JAK inhibitors. In a 12- week study of upadacitinib in 
RA, a dose- dependent reduction in NK cell counts was reported, 
with a mean decrease of 18.3% and 28.0% with upadacitinib at 
6 mg and 12 mg twice daily, respectively (33); the safety profiles 
were found to be comparable to those reported in a phase III study 
of upadacitinib in daily doses of 15 mg or 30 mg (34). The Euro-
pean Public Assessment Report for baricitinib describes a 20% 
decrease in NK cells, with recovery to near- baseline levels at week 
52 (35). Also, early increases in B cell counts that were sustained 
through ≥24 weeks were reported for baricitinib (36). An early 
increase in lymphocyte counts followed by a gradual decrease to 
baseline by ~1 year has been reported for baricitinib as well (37); 
however, the effects beyond 1 year have not been published, and 
it is unclear whether the lymphocytes reached steady state.
The initial increase in ALC with both adalimumab and tofaci-
tinib treatment in this study may be due to the initial amelioration 
of disease or, alternatively, to a direct/indirect effect of JAK inhi-
bition on lymphocyte trafficking and margination. In the absence 
of foreign antigens, cytokines such as IL- 7/IL- 15 provide survival 
and/or proliferation signals to maintain the population of CD4+ 
and CD8+ T cells (38–40). IL- 15 is also the dominant cytokine for 
prolonging NK cell survival (40,41). Therefore, long- term modu-
lation of cytokine signaling by tofacitinib, but not adalimumab or 
MTX, could impact the setpoint for steady- state populations of 
CD4+ T, CD8+ T, and NK cells, which compete for a limited pool 
of IL- 7/IL- 15. With decreased IL- 7/IL- 15 signaling, a reduction in 
NK cell numbers may be observed earlier than CD4+ and CD8+ 
T cells, due to the relatively shorter half- life of NK cells. With 
continued tofacitinib dosing, CD4+ and CD8+ T cell numbers 
decrease slowly to a new setpoint, reducing the competition for 
IL- 15. The increased availability of IL- 15, coupled with >10- fold 
higher expression of the IL- 15 receptor (CD122, IL- 2/IL- 15Rβ) on 
NK cells, may lead to a compensatory increase in IL- 15 signaling, 
resulting in a higher NK cell number setpoint after long- term dos-
ing (40,42). Upon treatment discontinuation, CD4+, CD8+, and 
NK cells all increase in response to increased cytokine signaling. 
The physiologic implications of the observed increase in circulat-
ing B cell numbers in response to JAK inhibition, followed by an 
eventual normalization after 4 years, are unclear. Overall, there is 
a lack of information concerning the mechanism of action for the 
effect of tofacitinib on ALC/LSC; hence, discussions can only be 
considered in hypothesis- generating terms.
The impact of immunotherapy on the immune system 
cannot be understood without considering both numerical and 
functional changes in immune cells, and several studies have 
been conducted to characterize the potential effect of tofac-
itinib on immune function, i.e., cell- mediated immunity (T cell 
and NK cell function) and humoral- mediated immunity (B cell 
and vaccination responses). Cell- mediated immunity data sug-
gest that tofacitinib does not significantly impair T cell function 
assessed via non–antigen- specific stimulation, nor does it affect 
the generation and maintenance of responses using antigens 
as varied as tetanus toxoid (study A3921061/NCT01163253) 
(ref. 21 and Supplementary Figure 3, on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40780/abstract) and herpesviruses (23). A modest decrease 
in NK cell cytotoxic activity was observed in tofacitinib- treated 
patients with RA (study A3921237/NCT02147587) (Supple-
mentary Figure 4, http://onlinelibrary.wiley.com/doi/10.1002/
art.40780/abstract); the clinical significance of these data is 
unclear, although the possibility of an impact on herpes zoster 
risk cannot be excluded. Similarly, studies measuring serum Ig 
levels and vaccination responses in tofacitinib- treated patients 
with RA and psoriasis suggest that tofacitinib may not impair 
humoral- mediated immunity (21–23).
This analysis had several limitations. Multiple patient pop-
ulations (some small), from several different studies, were eval-
uated. Also, most patients did not have baseline index study 
values for LSCs. Data on the All RA population were not eval-
uated continuously, and the LTE population is a selected pop-
ulation of patients tolerant to treatment, potentially limiting the 
generalizability of results. Protocol amendments prevented the 
inclusion of patients with lymphopenia (ALC <500 cells/mm3) 
and patients who developed confirmed  lym phopenia were 
withdrawn from the studies, making it difficult to capture infor-
mation on serious infections after the occurrence of confirmed 
lymphopenia. Finally, no direct investigation of the relationship 
between the level and function of ALCs/LSCs was performed.
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In conclusion, tofacitinib treatment results in a transient 
increase in ALC, followed by a gradual decline to reach steady 
state by ~48 months. Changes in both ALC and LSC are revers -
ible upon treatment cessation. Although the overall effects of 
tofaci tinib on cell- mediated and humoral- mediated immunity 
appear to be modest, risks of serious infections and herpes zos-
ter were generally increased in the setting of confirmed low ALCs 
(<500 cells/mm3). From a clinical perspective, evaluation of ALC 
at baseline and monitoring every 3 months during tofacitinib treat-
ment is recommended. Initiation of tofacitinib is not recommended 
in patients with an ALC of <500 cells/mm3, and if this develops, 
tofacitinib therapy should be discontinued (26). ALC and CD4+/
CD8+ T cell counts correlated well, and there was no strong cor-
relation between CD4+/CD8+ T cell counts and serious infections, 
suggesting that monitoring of these lymphocyte subsets may not 
provide any additional information. Thus, ALC monitoring alone 
appears to be adequate to minimize risk. Laboratory and safety 
outcomes related to immune function continue to be evaluated 
within the tofacitinib development program.
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